非酒精性脂肪性肝病患者血清chemerin、Vaspin、TXNIP水平研究及其相关性分析
|
摘要
目的探讨非酒精性脂肪性肝病患者血清趋化素(chemerin)、丝氨酸蛋白酶抑制剂(vaspin)、硫氧还蛋白结合蛋白(TXNIP)水平及其相关性。方法将86例非酒精性脂肪性肝病患者作为观察组,并取同期来院检查的56例健康人作为对照组,比较两组受试者的血清chemerin、vaspin、TXNIP、炎症因子以及胰岛素抵抗指数(HOMA-IR)水平变化,分析血清chemerin、vaspin、TXNIP水平与血清炎症因子以及HOMA-IR之间的相关性。结果观察组患者的血清chemerin、vaspin、TXNIP、TNF-α、CRP以及HOMA-IR水平均明显高于对照组(P<0.05)。NAFLD患者血清chemerin、vaspin、TXNIP水平与血清TNF-α、CRP以及HOMA-IR水平均呈现正相关(P<0.05)。结论非酒精性脂肪性肝病患者血清chemerin、vaspin、TXNIP水平显著高于正常健康人,且与血清TNF-α、CRP以及HOMA-IR水平均呈现正相关,具有一定的临床应用价值。
Objective To explore the levels of chemerin, serine protease inhibitor(vaspin), and thioxolin-binding protein(TXNIP) in patients with non-alcoholic fatty liver disease and their correlation, providing a reference for the clinical diagnosis and treatment of non-alcoholic fatty liver disease. Methods Eighty-six patients with nonalcoholic fatty liver disease admitted to our hospital from January 2017 to January 2018 were enrolled as the observation group. 56 healthy people who were admitted to the hospital during the same period were used as the control group. Serum chemerin, Vaspin, TXNIP, inflammatory factors and insulin resistance index(HOMA-IR) levels were compared between the two groups. The correlation between serum chemerin, Vaspin, TXNIP levels and serum inflammatory factors and HOMA-IR was analyzed. Results Serum chemerin, Vaspin, TXNIP, TNF-α, CRP and HOMA-IR levels were significantly higher in the observation group than in the control group(P<0.05). Serum chemerin, Vaspin and TXNIP levels in patients with NAFLD were positively correlated with serum TNF-α, CRP and HOMA-IR levels(P<0.05). Conclusion The serum levels of chemerin, Vaspin and TXNIP in patients with nonalcoholic fatty liver disease are significantly higher than those in normal healthy people, and they are positively correlated with serum TNF-α, CRP and HOMA-IR levels, and have certain clinical application value.
Objective To explore the levels of chemerin, serine protease inhibitor(vaspin), and thioxolin-binding protein(TXNIP) in patients with non-alcoholic fatty liver disease and their correlation, providing a reference for the clinical diagnosis and treatment of non-alcoholic fatty liver disease. Methods Eighty-six patients with nonalcoholic fatty liver disease admitted to our hospital from January 2017 to January 2018 were enrolled as the observation group. 56 healthy people who were admitted to the hospital during the same period were used as the control group. Serum chemerin, Vaspin, TXNIP, inflammatory factors and insulin resistance index(HOMA-IR) levels were compared between the two groups. The correlation between serum chemerin, Vaspin, TXNIP levels and serum inflammatory factors and HOMA-IR was analyzed. Results Serum chemerin, Vaspin, TXNIP, TNF-α, CRP and HOMA-IR levels were significantly higher in the observation group than in the control group(P<0.05). Serum chemerin, Vaspin and TXNIP levels in patients with NAFLD were positively correlated with serum TNF-α, CRP and HOMA-IR levels(P<0.05). Conclusion The serum levels of chemerin, Vaspin and TXNIP in patients with nonalcoholic fatty liver disease are significantly higher than those in normal healthy people, and they are positively correlated with serum TNF-α, CRP and HOMA-IR levels, and have certain clinical application value.
引文
[1] 赵倩,倪娟,孟祥英,等.血清免疫球蛋白检测在非酒精性脂肪性肝病患者肝纤维化诊断中的应用研究[J].贵州医药,2017,41(2):198-200.
[2] Mishra A,Younossi Z M.Epidemiology and natural history of non-alcoholic fatty liver disease[J].Journal of Clinical & Experimental Hepatology,2015,35(3):221-235.
[3] Lonardo A,Bellentani S,Argo C K,et al.Epidemiological modifiers of non-alcoholic fatty liver disease:Focus on high-risk groups[J].Digestive & Liver Disease,2015,47(12):997-1006.
[4] Poordad F,Gish R,Wakil A,et al.De novo non-alcoholic fatty liver disease following orthotopic liver transplantation[J].American Journal of Transplantation,2015,3(11):1413-1417.
[5] Isokuortti E,Zhou Y,Peltonen M,et al.Use of HOMA-IR to diagnose non-alcoholic fatty liver disease:a population-based and inter-laboratory study[J].Diabetologia,2017,60(10):1-10.
[6] Motamed N,Miresmail S J,Rabiee B,et al.Optimal cutoff points for HOMA-IR and QUICKI in the diagnosis of metabolic syndrome and non-alcoholic fatty liver disease:A population based study[J].Journal of Diabetes & Its Complications,2016,30(2):269-274.
[7] Ye J,Yao Z,Tan A,et al.Low Serum sex hormone-binding globulin associated with insulin resistance in men with nonalcoholic fatty liver disease[J].Horm Metab Res,2017,49(5):359-364.
[8] Calzadilla Bertot Luis,Adams Leon Anton.The Natural course of non-alcoholic fatty liver disease[J].International Journal of Molecular Sciences,2016,17(5):774-782.
[9] Kajor M,Kukla M,Waluga M,et al.Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease[J].Polish Journal of Pathology Official Journal of the Polish Society of Pathologists,2017,68(2):117-127.
[10] Hamza RT,Elkabbany ZA,Shedid AM,et al.Serum chemerin in obese children and adolescents before and after l-carnitine therapy:relation to nonalcoholic fatty liver disease and other features of metabolic syndrome[J].Archives of Medical Research,2016,47(7):541-549.
[11] Boutari C,Perakakis N,Mantzoros C S.Association of Adipokines with development and progression of nonalcoholic fatty liver disease[J].Endocrinology & Metabolism,2018,33(1):33-43.
[12] Mohamed A A,Sabry S,Abdallah A M,et al.Circulating adipokines in children with nonalcoholic fatty liver disease:possible noninvasive diagnostic markers[J].Ann Gastroenterol,2017,30(4):457-463.
[13] Mohamed A A,Sabry S,Abdallah A M,et al.Circulating adipokines in children with nonalcoholic fatty liver disease:possible noninvasive diagnostic markers[J].Ann Gastroenterol,2017,30(4):457-463.
[14] Zhang X,Zhang J H,Chen X Y,et al.Reactive oxygen species-induced txnip drives fructose-mediated hepatic inflammation and lipid accumulation through nlrp3 inflammasome activation[J].Antioxid Redox Signal,2015,22(10):848-870.
[15] Montazerifar F,Bakhshipour A R,Karajibani M,et al.Serum omentin-1,vaspin,and apelin levels and central obesity in patients with nonalcoholic fatty liver disease[J].Journal of Research in Medical Sciences the Official Journal of Isfahan University of Medical Sciences,2017,22(1):70-79.
[2] Mishra A,Younossi Z M.Epidemiology and natural history of non-alcoholic fatty liver disease[J].Journal of Clinical & Experimental Hepatology,2015,35(3):221-235.
[3] Lonardo A,Bellentani S,Argo C K,et al.Epidemiological modifiers of non-alcoholic fatty liver disease:Focus on high-risk groups[J].Digestive & Liver Disease,2015,47(12):997-1006.
[4] Poordad F,Gish R,Wakil A,et al.De novo non-alcoholic fatty liver disease following orthotopic liver transplantation[J].American Journal of Transplantation,2015,3(11):1413-1417.
[5] Isokuortti E,Zhou Y,Peltonen M,et al.Use of HOMA-IR to diagnose non-alcoholic fatty liver disease:a population-based and inter-laboratory study[J].Diabetologia,2017,60(10):1-10.
[6] Motamed N,Miresmail S J,Rabiee B,et al.Optimal cutoff points for HOMA-IR and QUICKI in the diagnosis of metabolic syndrome and non-alcoholic fatty liver disease:A population based study[J].Journal of Diabetes & Its Complications,2016,30(2):269-274.
[7] Ye J,Yao Z,Tan A,et al.Low Serum sex hormone-binding globulin associated with insulin resistance in men with nonalcoholic fatty liver disease[J].Horm Metab Res,2017,49(5):359-364.
[8] Calzadilla Bertot Luis,Adams Leon Anton.The Natural course of non-alcoholic fatty liver disease[J].International Journal of Molecular Sciences,2016,17(5):774-782.
[9] Kajor M,Kukla M,Waluga M,et al.Hepatic chemerin mRNA in morbidly obese patients with nonalcoholic fatty liver disease[J].Polish Journal of Pathology Official Journal of the Polish Society of Pathologists,2017,68(2):117-127.
[10] Hamza RT,Elkabbany ZA,Shedid AM,et al.Serum chemerin in obese children and adolescents before and after l-carnitine therapy:relation to nonalcoholic fatty liver disease and other features of metabolic syndrome[J].Archives of Medical Research,2016,47(7):541-549.
[11] Boutari C,Perakakis N,Mantzoros C S.Association of Adipokines with development and progression of nonalcoholic fatty liver disease[J].Endocrinology & Metabolism,2018,33(1):33-43.
[12] Mohamed A A,Sabry S,Abdallah A M,et al.Circulating adipokines in children with nonalcoholic fatty liver disease:possible noninvasive diagnostic markers[J].Ann Gastroenterol,2017,30(4):457-463.
[13] Mohamed A A,Sabry S,Abdallah A M,et al.Circulating adipokines in children with nonalcoholic fatty liver disease:possible noninvasive diagnostic markers[J].Ann Gastroenterol,2017,30(4):457-463.
[14] Zhang X,Zhang J H,Chen X Y,et al.Reactive oxygen species-induced txnip drives fructose-mediated hepatic inflammation and lipid accumulation through nlrp3 inflammasome activation[J].Antioxid Redox Signal,2015,22(10):848-870.
[15] Montazerifar F,Bakhshipour A R,Karajibani M,et al.Serum omentin-1,vaspin,and apelin levels and central obesity in patients with nonalcoholic fatty liver disease[J].Journal of Research in Medical Sciences the Official Journal of Isfahan University of Medical Sciences,2017,22(1):70-79.